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Spinal muscular atrophy (SMA) is a rare, autosomal recessive neuromuscular degenerative
disease characterized by loss of spinal cord motor neurons leading to progressive muscle
wasting. The most common pathology results from a homozygous disruption in the
survival motor neuron 1 (SMN1) gene on chromosome 5q13 via deletion, conversion, or
mutation. SMN2 is a near duplicate of SMN1 that can produce full-length SMN mRNA
transcripts, but its overall production capability of these mRNA transcripts is lower than
that seen in SMN1. This leads to lower levels of functional SMN protein within motor
neurons. The FDA approved nusinersen in December 2016 to treat SMA associated with
SMN1 gene mutation. It is administered directly to the central nervous system by
intrathecal injection. An antisense oligonucleotide (ASO) drug, nusinersen, provides an
upcoming and promising treatment option for SMA and represents a novel
pharmacological approach with a mechanism of action relevant for other
neurodegenerative disorders. Nusinersen begins with four initial loading doses that are
followed by three maintenance doses per year. Three major studies (CHERISH, ENDEAR,
and NURTURE) have shown to improve motor function in early and late-onset individuals
and reduce the chances of ventilator requirements in pre-symptomatic infants. Studies
investigating the timing of drug delivery in mouse models of SMA report the best
outcomes when drugs are delivered early before any significant motor function is lost.
Nusinersen is a novel therapeutic approach with consistent results in all three studies and
is proof of the novel concept for treating SMA and other neurodegenerative disorders in
the future.

INTRODUCTION
Spinal muscular atrophy (SMA) is a rare, autosomal recessive neuromuscular degenerative disease characterized by
loss of spinal cord motor neurons leading to progressive
muscle wasting. The most common pathology results from
a homozygous disruption in the survival motor neuron 1
(SMN1) gene on chromosome 5q13 via deletion, conversion,
or mutation.1 In a large multi-ethnic study to test the feasibility of high-throughput genetic testing for SMA carriers,
the overall carrier frequency was established as 1 in 54 with
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an incidence of 1 in 11,000.2 SMA is broken down into various levels of severity with classification into four main phenotypes based on age and level of motor function. Type 1
is considered the most severe and seen within six months
of life. It presents with hypotonia, areflexia, and significant
muscle weakness. The FDA approved nusinersen in December 2016 to treat SMA associated with SMN1 gene mutation.
It is administered directly to the central nervous system by
intrathecal injection. Nusinersen became the first approved
treatment for SMA with an orphan drug designation in the
United States and Europe. An antisense oligonucleotide
(ASO) drug, nusinersen, provides an upcoming and promis-
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ing treatment option for SMA and represents a novel pharmacological approach with a mechanism of action relevant
for other neurodegenerative disorders.3 ASO therapies inhibit gene expression by binding to messenger RNA
(mRNA), causing them to be cut into pieces that intervene
with the creation of coded proteins. The principal pharmacological action mechanism of the 2ʹ-O-methoxyethyl
phosphorothioate modified drug nusinersen alters the
SMN2 pre-mRNA splicing process by inhibiting splicing factors.3 Nusinersen increases exon 7 inclusions in survival
motor neuron 2 (SMN2) mRNA transcripts, which increases
the production of full-length SMN proteins. Three major
studies (CHERISH, ENDEAR, and NURTURE) have shown to
improve motor function in early and late-onset individuals and reduce the chances of ventilator requirements in
pre-symptomatic infants. Nusinersen begins with four initial loading doses that are followed by three maintenance
doses per year. The more common side effects of nusinersen
include lower respiratory infection, fever, constipation,
headache, vomiting, back pain, post-lumbar puncture syndrome, increase risk of kidney damage, and bleeding complications. If indicated, Nusinersen is a viable option to
treat SMA as it is one of the few SMN enhancing medications available today.

SPINAL MUSCULAR ATROPHY

the telomeric (SMN1) and the centromeric (SMN2).10 SMN2
is nearly identical to SMN1 but is a poor replacement in
SMA patients as a single substitution at position 840 leads
to the exclusion of exon 7 when transcribed.10 As a result,
this mRNA missing exon 7 produces a shortened, nonfunctional protein quickly degraded.10 However, the exclusion
of exon 7 is incomplete as 10-15% of the mRNA transcripts
from SMN2 retain exon 7; these mRNA transcripts encode
the normal functional SMN protein and provide some but
reduced functionality.10
SMN protein is a ubiquitous protein present in the cytoplasm and nucleus as a part of a complex vital to small
nuclear ribonuclear protein (snRNPs) production.10 The
snRNPs are involved in the splicing of pre-mRNA into
mRNA and are essential in various cellular housekeeping
functions.11 Due to this functional importance, the therapeutic focus is shifted to the function of SMN proteins and
how they make lower motor neurons susceptible to degeneration. One study suggests that low levels of SMN protein create a negative feedback loop specific to lower motor
neurons where decreases in exon 7 inclusion further decrease the splicing of its mRNA.11,12 Other studies suggest
that SMN’s role in axonal transport and actin dynamics may
contribute to the motor neuron-specific pathology.11,13,14
Nonetheless, SMN’s involvement in multiple pathways and
cellular functions points to motor neuron degeneration as
the final common outcome from multiple upstream
causes.11
RISK FACTORS

EPIDEMIOLOGY

Estimating the prevalence and incidence of SMA has a
unique set of challenges to consider. Many studies that attempted to quantify SMA epidemiology were performed before discovering the genetic cause behind SMA, forcing
older studies to rely on clinical features alone.4 Additionally, many studies were conducted in small geographic locations where a mildly elevated population with SMA can
drastically affect the final calculations of incidence and
prevalence.4–6 Nonetheless, SMA of any type is a rare disease with an estimated incidence of roughly 10 in 100,000
live births.4 When all types of SMA are considered together,
the prevalence is estimated to be approximately 1-2 per
100,000 persons.4 Type 1 SMA is the deadliest form of the
disease and presents an inherent challenge in assessing its
prevalence as patients often die as early as one year of age.4
The prevalence of SMA type 1 is estimated to be between
0.04 and 0.28 per 100,000, but the accuracy of these figures is limited by the short life span in these patients.4,7,8
This contrasts with the milder forms of SMA, types 2 and
3, where patients often survive into early adulthood and
beyond, allowing better prevalence estimates. Taking SMA
type 2 and 3 together, prevalence is nearly 1.5 per
100,000.4,9
PATHOPHYSIOLOGY

The pathophysiology of all types of SMA originates from a
homozygous deletion of the SMN1 gene present on chromosome 5q13 that functions to produce survival motor neuron (SMN) proteins.10 Humans have two forms of this gene:

An autosomal recessive disease, the risk of developing SMA
is associated with a carrier frequency in the population. An
analysis looking at different ethnicities over multiple geographic locations discovered Caucasians and Asians generally possess higher carrier frequencies for SMN1 mutations
but were not significantly higher than those of other ethnic groups.4 Notable risk factors for developing SMA were
identified, including consanguinity. One study of an Egyptian community where over half of the affected families displayed some degree of consanguinity identified an incidence of 250 in 100,000 live births.4
Risk factors for the progression of SMA to its most severe
life-threatening complications were later analyzed. The
most life-threatening point of progression was feeding
problems.15 These include behaviors such as difficulties
with chewing, choking while eating, and dysphagia.15 While
some of these difficulties may not develop in the milder
forms of SMA (types 2 and 3), they almost always are seen
in those with type 1.15 One study illustrated that as high as
44% of patients with SMA type 2 and 3 develop some sort of
feeding difficulty, and 10% will develop aspiration leading
to hospitalization.15
CLINICAL PRESENTATION

Although the lack of SMN1 genotypically defines SMA, the
clinical presentation and the overall severity of the disease
state are determined mainly by the copy number of the
SMN2 gene in the patient’s genome.16 Patients will possess
variable copy numbers between 0 and 8 of the SMN2 gene,
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where more significant numbers of SMN2 correlate with
more severity.11 SMN2 is a near duplicate of SMN1 that can
produce full-length SMN mRNA transcripts, but its overall production capability of these mRNA transcripts is lower
than that seen in SMN1. This leads to lower levels of functional SMN protein within motor neurons.16 Patients with
SMA type 1, the most severe form of the disease, will present in the first few months of life with lower motor neuron
signs such as extremity weakness, absent deep tendon reflexes, and intercostal muscle weakness with intact sensations.16 Historically, those with type 1 have died within
the first few years of life as muscle weakness eventually
led to feeding difficulties, consequential failure to thrive,
and swallowing dysfunction with an ensuing risk of aspiration.16 Patients with SMA type 2 have a less severe but
still debilitating presentation that usually starts between
6 and 18 months old.16 Patients with type 2 SMA left untreated will lose the ability to stand and walk independently
and possess the same risk for respiratory and feeding difficulties as type 1 but at a slower onset and have a more
mild muscle weakness.1,16 Type 3 and 4 are considered the
mildest forms of SMA. Patients with type 3 have sufficient
copies of SMN2, allowing adequate production of functional
SMN protein, and often can avoid the severe life-threatening complications seen in those with type 1.16 Patients may
develop gross motor skills normally initially. Still, after 18
months of age, they present with falls and regression that
may worsen over time.16 SMA type 4, the least debilitating
of the four, often presents in adulthood with highly variable motor symptomology, making it a difficult diagnostic
case as other neurologic diseases must first be ruled out.1
Although the copy number of SMN2 is the primary factor
in determining the severity of the illness. Phenotypic variations can occur from certain exon 7 mutations, creating
splice-enhancing elements and more functional SMN protein production.10 This pathology is less common but shows
how various changes in SMA genotypes can clinically present.

of cyanosis or pallor.17,18 Respiratory support include assistance in airway clearance (e.g., manual cough assist, mechanical insufflation-exsufflation, postural drainage), noninvasive ventilation, and, in severe cases, tracheostomy.17
Nutritional deficits associated with SMA stem from bulbar dysfunction, which impairs swallowing capability.
Those with SMA types 1 or 2 are at increased risk of malnutrition, and those with less severe symptoms are at higher
risk of obesity.17 Swallowing difficulties may be managed
with semisolid diets or feeding through nasogastric or gastrostomy tubes, either as a supplement or replacement for
oral feeding.17 Another major cause of morbidity and mortality for SMA patients is the increased risk for gastroesophageal reflux, putting patients at a higher risk for silent
aspiration, consequent pneumonia, and other respiratory
complications.18–20 Reflux can be managed with antacids
and agents that block acid secretion, such as proton pump
inhibitors or histamine blockers.17,20
A large portion of SMA patients will develop orthopedic
disorders, including joint contractures, hip subluxation or
dislocation, scoliosis, and mobility difficulties. Physical
therapy, mobility equipment, orthoses, and braces can alleviate most of these disorders, whereas more severe instances of scoliosis and hip subluxation/dislocation warrant
surgery.18 Scoliosis is particularly concerning as it is present in roughly 60-95% of SMA patients, and the progression of scoliosis can exacerbate respiratory dysfunction and
gastroesophageal reflux.18,21 Surgical intervention is most
often indicated for progressive scoliosis in patients with
SMA types 2 or 3. While surgical correction cannot reverse
losses in lung capacity resulting from scoliosis, the correction significantly improves the quality of life and slows further deterioration of respiratory function.22,23 After skeletal maturity in adolescence, patients often undergo
posterior spinal fusion with iliac fixation to assist correction of pelvic obliquity.18

CURRENT TREATMENT OF SPINAL MUSCULAR
ATROPHY

Over the past two decades, several pharmacologic agents
have been investigated as potential treatments for SMA.
The main treatment strategies can be categorized into four
groups: promoting the survival of motor neurons, enhancing muscular function, introducing exogenous copies of the
SMN1 gene, and modulating transcription of the SMN2 gene
to produce full-length gene products.
One neuroprotective agent, olesoxime, acts by decreasing the permeability of mitochondrial membranes during
stress, inhibiting the release of pro-apoptotic factors and
promoting the survival of motor neurons.24,25 Olesoxime
showed early promise in cell cultures and mouse models,
but a phase II clinical trial failed to meet its primary endpoint, causing an abrupt stop in the development of the
drug in 2018.18,24,26 Other neuroprotective agents like
gabapentin and riluzole were briefly investigated as treatments for SMA in the early 2000s, but data from early clinical trials did not support the drug’s efficacy in treating
SMA.27–29
The fast skeletal muscle troponin activator, reldesemtiv,
increases contractility and limits fatigue by slowing calcium
release from troponin in fast skeletal muscle fibers.24,25,30

MANAGEMENT OF COMPLICATIONS

The leading cause of morbidity and mortality among patients with SMA is respiratory complications such as impaired coughing ability, hypoventilation (especially during
sleep), recurrent infections, and hypoplasia of the lungs and
chest wall.17,18 These symptoms are caused mainly by progressive weakening of expiratory and intercostal muscles
with mostly preserved diaphragm innervation.17 Monitoring respiratory muscle functions quantitatively with peak
cough flow, maximal inspiratory pressures, and maximal
expiratory pressures is often difficult as many patients are
too young or too weak to undergo testing. Respiratory functions can be gauged more practically through a targeted
physical exam that assesses respiratory rate, work of
breathing, presence of paradoxical breathing, and presence

PHARMACOLOGIC TREATMENTS
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Phase II clinical trials showed significant increases from
baseline on 6-minute walk distances and maximal expiratory pressure for patients with SMA types 2, 3, and 4. Still,
several other measures of neuromuscular function illustrated no significant change.25,30–32 Further studies are in
the planning stages and may involve a combination of
reldesemtiv with other therapies.30 Pyridostigmine (an
acetylcholinesterase inhibitor) and SRK-015 (a myostatin
inhibitor) are also currently under investigation for SMA
treatment. Both are now in phase II clinical trials, with the
final results pending.33,34
The next class of treatments aims to correct the underlying genetic defect in SMA rather than improving neuromuscular function. Two small molecule drugs, branaplam and
risdiplam, act by promoting the inclusion of exon 7 of the
SMN2 gene during transcription, increasing levels of fulllength SMN proteins.30 Branaplam showed early promise in
its safety and efficacy, but development was halted briefly
after preclinical toxicology studies showed nerve damage
as a possible side effect.35,36 This issue has then been resolved, and phase I/II trials are currently developing the
drug.35 Risdiplam, in contrast, has demonstrated clear
safety and efficacy and is now in phase II/III clinical trials.30
Nusinersen acts through a similar mechanism to promote
the inclusion of exon 7 in SMN2 gene products, but the form
of the drug is an antisense oligonucleotide rather than a
small molecule.30 The mechanism of action of nusinersen
will be explored in greater detail later in this review.
A more direct approach to correcting the genetic defect
underlying SMA, zolgensma (known as AVXS-101), delivers
an intact copy of the wild-type SMN1 gene through an
adeno-associated viral serotype 9 (AAV9) vector.24 In phase
I trials, zolgensma showed significant results in improving
survival, motor function, and milestones in infant patients
with SMA type 1, with the only notable side effect being
transaminitis.37 Phase II and III clinical trials yielded similar positive results, and zolgensma was approved by the
FDA in May 2019 for intravenous administration in SMA
patients under two years of age. Additional trials are underway for intrathecal administration and the use of zolgensma in pre-symptomatic patients. Currently, zolgensma
and nusinersen are the only two FDA-approved direct treatments for SMA.24
Early detection and diagnosis of SMA are critical in preventing irreversible loss of motor function and muscular
atrophy. For patients with the most severe form of SMA
(type 1), irreversible loss of motor neurons begins perinatally with loss of more than 90% of motor units within the
first six months of life.25,38,39 Studies investigating the timing of drug delivery in mouse models of SMA report the best
outcomes when drugs are delivered early before any significant motor function is lost.18,40 Obtaining the maximum
benefit from any SMA treatment hinges on thorough newborn screening and early intervention.

NUSINERSEN PHARMACOLOGIC
CONSIDERATIONS
Nusinersen has been approved and designated as a treatment for spinal muscular atrophy in all stages of life. Nusin-

ersen was approved for all 5q-associated SMA types by the
FDA in December 2016 and the European Medicines Agency
(EMA) in July 2017.3 It is available as an injection administered directly to the central nervous system intrathecally
by a trained health care provider. The recommended dosage
of nusinersen is 12 mg (5 mL) per administration. It is usually given as four initial doses, once every two weeks for the
first three doses and 30 days after the third dose. After the
loading dose is complete, it is then given once every four
months. Common side effects include lower respiratory infection, fever, constipation, headache, vomiting, back pain,
and post-lumbar puncture syndrome. Regular blood and
urine testing are required due to the increased risk of kidney
damage and bleeding complication. Risks associated with
pregnancy are not clearly defined due to a lack of sufficient
data. No adverse effects on embryo-fetal development were
observed in animal studies in which nusinersen was administered by subcutaneous injection to mice and rabbits during pregnancy.41 Clinical trials have determined the safety
and efficacy of nusinersen on the pediatric population and
have shown no effect in juvenile monkeys with 0.3mg per
dose. Nusinersen has orphan drug designation in the United
States and Europe.
MECHANISM OF ACTION

Nusinersen is a survival motor neuron-2 (SMN2)-directed
antisense oligonucleotide (ASO) designed to treat SMA
caused by a deficiency in SMN proteins secondary from mutations in chromosome 5q.42 ASO therapies inhibit gene expression by binding to messenger RNA (mRNA); this facilitates breakdown and interferes with protein production.
In vitro studies have shown nusinersen to increase exon
7 inclusion into the SMN2 mRNA transcripts, which enhances SMN protein production and increases the amount
of full-length SMN proteins. The 2ʹ-O-methoxyethyl phosphorothioate ASO seen in nusinersen inhibits splice-altering oligonucleotides on SMN2, displacing the intronic
splice silencing site 1 (ISS-1) between exons 7 and 8 and allowing a complete translation of SMN protein for the SMN2
gene.
PHARMACOKINETICS

Nusinersen’s pharmacokinetics within the CSF and CNS are
of great importance to understanding its usefulness in
treating SMA as the CNS tissues are nusinersen’s main site
of action.43 The pharmacokinetics can be analyzed using
a four-compartment model that considers the drug’s diffusion into and out of the CSF and CNS tissues.44 An analysis with ELISA and electrochemiluminescence quantifying
levels of nusinersen in the CSF and CNS tissues illustrated
the drug was rapidly taken up by CNS tissues (the cervical,
thoracic, and lumbar spinal cord with low levels) and then
was found in the CSF shortly.45 Furthermore, uptake into
the lumbar area tissues from the CSF is nearly twice as fast
as uptake within the cervical and thoracic regions. However, this may be due to the relatively higher concentration
gradient at the injection site during a lumbar puncture.45
After the drug enters the CNS tissues, it must first move
back into the CSF before being cleared into systemic circu-
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lation where it is no longer active.46 Nusinersen distributes
from the CSF into CNS tissues 4 to 20 fold faster than it diffuses back out of these tissues during its clearance phase.45
This may help explain nusinersen’s long median half-life of
163 days in the CSF and support dosing at intervals of 4-6
months.44,45 The plasma serves as the main clearance site
for nusinersen by the action of exonuclease hydrolysis and
urinary excretion, and current studies have not found the
support of degradation by cytochrome P450 enzymes.43,46

CLINICAL TRIALS: SAFETY AND EFFICACY

itoring visits occurring on days 8, 85, 260, 442, 624, and
715. After the study, Mean HFMSE scores, ULM scores, and
6MWT distances had improved (HFMSE: SMA type 2, +10.8
points; SMA type 3, +1.8 points; ULM: SMA type 2, +4.0
points; 6MWT: SMA type 3, +92.0 meters). Mean CMAP values remained relatively stable, and zero children discontinued treatment due to adverse events. Data from this trial
gave evidence of clinically significant long-term improvements in motor function and stabilization of disease activity in patients with later-onset SMA, as well as an acceptable safety profile for the drug.49,50

PHASE I STUDY

PHASE II STUDIES

In an open-label phase I study (NCT01494701), nusinersen
was administered by intrathecal injection to patients with
type 2 and type 3 SMA, aged 2–14 years. This study aimed to
evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of nusinersen. Ascending doses of 1, 3, 6,
and 9 mg were administered to a total of 28 participants (n =
6 in the first 3 dose cohorts, and n = 10 in the 9 mg cohort).
The study began with the 1 mg dose cohort, and then each
dose level was evaluated for safety before proceeding to the
next level. Periodic follow-ups included safety assessments
(collection of adverse events, physical/neurologic examinations, vital signs, clinical laboratory tests, and ECGs) and
collecting CSF and plasma samples to analyze safety and
pharmacokinetics. For preliminary clinical outcome measurements, the Hammersmith Functional Motor Scale Expanded (HFMSE) and Pediatric Quality of Life Inventory
were used. The drug was well-tolerated, with no serious adverse events reported and no clinically significant changes
in vital signs, neurologic or physical examinations, clinical laboratory tests, or ECGs. Plasma and CSF drug levels
were dose-dependent, and nusinersen’s half-life in CSF was
found to be 4–6 months. A significant increase in HFMSE
scores was observed at the 9 mg dose at 3 months post-dose
(3.1 points; p = 0.016), which increased even further at 9–14
months post-dose (5.8 points; p = 0.008) during an extension study (NCT01780246). This study provided clear support for the safety and tolerability of nusinersen, as well as
promising preliminary data on its efficacy.47,48

While phase I trials focused on patients with later-onset
SMA, phase II trials primarily explored the safety and efficacy of nusinersen in the treatment of infantile-onset SMA.
One open-label dose-escalation study enrolled 20 infants (3
weeks – 7 months of age) with type 1 SMA. This clinical
trial aimed to establish a safety profile, study pharmacokinetics, and demonstrate efficacy in improving motor function and extending patients’ lifespans. One cohort (n = 4)
was administered 3 doses of 6 mg intrathecal nusinersen
on days 1, 15, and 85. The second cohort (n = 16) was administered 12 mg doses on the same dosing schedule; both
had periodic follow-ups to assess safety. Clinical efficacy
was measured through event-free survival (time to death,
or time to permanent assisted ventilation), change from
baseline of compound muscle action potentials, and two
assessments of motor function: the motor milestones portion of the Hammersmith Infant Neurological Exam-Part 2
(HINE-2) and the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) motor function test. Autopsy tissue was also analyzed for pharmacologic activity.
In the 12 mg dose group, incremental achievements of
motor milestones (p < 0.0001), improvements in CHOP-INTEND motor function scores (p = 0.0013), and increased
compound muscle action potential amplitude of the ulnar
nerve (p = 0.0103) and peroneal nerve (p < 0.0001), compared with baseline, were observed. The cohort’s KaplanMeier survival curve also diverged from a published national history case series (p = 0.0014). Analysis of autopsy
tissue from patients exposed to nusinersen showed drug
uptake into motor neurons throughout the spinal cord, exposure at therapeutic concentrations, and increased SMN2
mRNA exon 7 inclusion and SMN protein concentrations
in the spinal cord. All participants reported severe adverse
events, but the authors considered all events to be unrelated to nusinersen. In all, this study showed acceptable
safety of multiple-dose intrathecal nusinersen in SMA type
1 patients, demonstrated pharmacokinetics consistent with
the drug’s mechanism of action, and supported nusinersen’s clinical efficacy.51
Patients with homozygous deletions in the SMN1 gene
are expected to develop symptoms of SMA, with varying degrees of severity based on the number of intact gene copies
of SMN2 present.52 Aiming to quantify nusinersen’s ability
in the proactive treatment of SMA, the NURTURE study
(NCT02386553) investigated the efficacy of nusinersen for
pre-symptomatic patients. 25 infants with documented

PHASE I/II STUDY

In a 253-day open-label, multiple-dose, multicenter phase
Ib/IIa study (NCT01703988) with a 715-day extension study
(NCT02052791), the long-term efficacy and safety of nusinersen were investigated. Similar to the previous study, this
clinical trial enrolled children between the ages of 2 and
15 years with type 2 (n = 11) and type 3 (n = 17) SMA and
used an escalating dose (3, 6, 9, and 12 mg; n = 8, n = 8, n
= 9, n = 9, respectively) format. Participants were administered 3 doses of intrathecal nusinersen on days 1, 29, and
85 of the study, and safety monitoring follow-ups were conducted on days 8, 36, 92, 169, and 253. Efficacy was measured through HFMSE scores, as well as Upper Limb Module (ULM), 6 Minute Walk Test (6MWT), compound muscle
action potential (CMAP), and quantitative multipoint incremental motor unit number estimation. In the 715-day extension study, the participants were administered 4 doses
of 12 mg nusinersen at 6-month intervals, with safety mon-
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SMN1 deletions were enrolled in the study, with 15 having
two copies of SMN2 and 10 having three copies. All participants had no clinical signs or symptoms of SMA at the beginning of the study, were younger than the expected age
of onset for symptoms in SMA types 1 and 2, and had baseline CMAP amplitudes of ≥1 mV. Nusinersen was administered in 4 loading doses of 12 mg each on days 1, 15, 29, and
64 of the study followed by maintenance dosing every 119
days. At the time of analysis, the participants were a median
34.8 months of age, past the expected age of symptom onset for SMA types 1 and 2. All subjects were living, and none
required tracheostomy or permanent ventilation. Four participants with two SMN2 copies utilized respiratory support
for ≥ 6 hours per day for ≥ 7 consecutive days that was initiated during acute, reversible illnesses. All 25 participants
achieved the ability to sit without support, 23/25 achieved
walking with assistance, and 22/25 achieved walking independently. Eight infants had adverse events possibly related
to nusinersen. Drug-related adverse events may be a reason for mild concern. Still, overall, the data collected from
this study indicate that the pre-symptomatic treatment of
SMA can improve patients’ outcomes through genetic testing. They highlight the importance of thorough newborn
screening. A placebo-controlled trial would be required to
claim absolute significance in the efficacy of the drug, but
the study’s results are promising, nonetheless.53
PHASE III STUDIES

Phase III studies on nusinersen generally follow the same
structure as earlier clinical trials with the addition of a
placebo-controlled group. The double-blind, placebo-controlled ENDEAR trial (NCT02193074) was mainly designed
after the NURTURE study.53 121 infants (n = 80 for the
nusinersen group, n = 41 for the control group) with documented homozygous deletions of SMN1 were enrolled in
the trial. However, all the participants were symptomatic at
the time of enrollment in contrast to the NURTURE study.
In the nusinersen group, the drug was administered in four
doses of 12 mg each on days 1, 15, 29, and 64 of the study,
while the placebo group had sham procedures on the same
days. The primary endpoints for this study were motor
milestone responses (quantified by HINE-2 scores) as well
as event-free survival. Efficacy assessments were scheduled
on days 64, 183, 302, and 394, and safety assessments were
scheduled on the same days with the addition of days 16
and 30. A prespecified interim analysis after 80 infants had
been enrolled for at least 6 months yielded a benefit-cost
analysis favoring nusinersen. This prompted the early termination of the trial with any remaining assessments carried out at the end-of-study visit. The final analysis showed
that a significantly higher percentage of infants in the
nusinersen group than that in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37
[0%]). The likelihood of event-free survival was higher in
the nusinersen group than that in the control group (hazard
ratio for death or the use of permanent assisted ventilation,
0.53; p = 0.005). The incidence rate of adverse events was
similar between the two groups. Participants with a shorter
duration of illness at the time of screening were more likely
to benefit from treatment with nusinersen over those with

a longer duration of illness, highlighting the great need for
effective newborn screening and early detection.54 An additional trial, the Expanded Access Program (NCT02865109),
sought to reinforce the results of the ENDEAR trial and
confirm its validity for SMA type 1 patients older than 7
months. The study followed a very similar structure, and
its results were consistent with the ENDEAR study’s data in
terms of safety and efficacy.55
The double-blind, placebo-controlled CHERISH trial
(NCT02292537) followed a similar format, but the participants were children who had symptom onset after 6 months
of age. Participants (n = 126; n = 84 for nusinersen group,
n = 42 for control group) underwent intrathecal administration of 12 mg of nusinersen (nusinersen group) or a sham
procedure (control group) on days 1, 29, 85, and 274 of
the trial. The primary endpoint for this study was changed
from the baseline of HFMSE scores. Secondary endpoints
include the percentage of participants with a clinically significant increase in HFMSE score (≥ 3 points). Similar to
the ENDEAR trial, the CHERISH trial included a prespecified interim analysis at 15 months. The interim analysis
reported significant results in favor of nusinersen, which
again prompted the early termination of the trial. The leastsquares mean an increase in HFMSE score from baseline to
month 15 was 4.0 in the nusinersen group and -1.9 in the
control group. In the final analysis, 57% of the nusinersen
group had an increase in HFMSE score of ≥ 3 points, in contrast to only 26% of the control group (p < 0.001). The incidence of adverse effects was similar in both groups. This
trial served to reinforce the growing body of evidence that
nusinersen is safe and effective for use in the treatment of
all forms of SMA.56

CONCLUSION
SMA, a neurodegenerative disease affecting spinal anterior
horn cells, is a rare disease with an estimated incidence of
roughly 10 in 100,000 live births and a prevalence estimated
to be approximately 1-2 per 100,000 when all types are considered together.4 The leading cause of morbidity and mortality among patients with SMA revolves around respiratory
complications: impaired coughing ability, hypoventilation,
recurrent infections, and hypoplasia of the lungs and chest
wall.17,18 Studies have shown the disruption in the SMN1
gene to be the cause of SMA. Although SMA is genotypically defined by the lack of SMN1, the clinical presentation
and the overall severity of the disease state is determined
mainly by the copy number of SMN2 gene present in an affected patient’s genome.16 Since identifying the SMN1 gene
locus in 1990 and its homologue SMN2 gene copy in 1995,
a major effort has been devoted to providing potential therapeutic interventions such as replacing SMN1 or decreasing SMN2 exon skipping to increase the total amount of
SMN proteins.3 Over the last 50 years, planned and realized applications in the field of antisense and nucleic acid
nanotechnologies have produced astonishing results and
posed new challenges for further developments, exemplifying the essence of the post-genomic era.57 ASOs are defined as chemically synthesized oligonucleotides, generally
12–30 nucleotides in length, designed to bind to RNA.58
The various sizes and chemical structures tend to determine
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Table 1. Clinical Safety and Efficacy
Author
(Year)

Groups Studied and Intervention

Results and Findings

Conclusions

Chiriboga
C. et al.
(2016)47

Phase I, open-label doseescalation study. Participants (n =
28) were patients with SMA
types 2 or 3, aged 2–14 years.
Nusinersen was given in 1, 3, 6,
and 9 mg doses. The authors
monitored adverse events and
examined the pharmacokinetics
of the drug in CSF and plasma.
HFMSE scores were evaluated at
3 months and 9–14 months postdose.

No serious adverse events were
reported, and the safety of the
drug was established. Plasma and
CSF drug levels were dosedependent, and the drug had a
half-life in CSF of 4–6 months.
Significant increases from
baseline in HFMSE for the 9 mg
dose cohort were observed at 3
months post-dose (3.1 points; p =
0.016) and 9–14 months postdose (5.8 points; p = 0.008).

Nusinersen was safe, welltolerated, and showed promising
preliminary clinical outcome data.

Darras B. et
al. (2019)49

Phase Ib/IIa, open-label,
multicenter, multiple-dose, doseescalation study. Participants (n =
28) were patients with SMA
types 2 or 3, aged 2–15 years. 3
doses of 3, 6, 9, or 12 mg
nusinersen were administered
intrathecally over three sessions,
and safety was monitored
throughout the trial. The
extension involved 4 doses of 12
mg administered at 6-month
intervals. Measures of motor
function were evaluated.

Mean HFMSE scores, ULM
scores, and 6MWT distances had
improved (HFMSE: SMA type II,
+10.8 points; SMA type III, +1.8
points; ULM: SMA type II, +4.0
points; 6MWT: SMA type III,
+92.0 meters). Mean CMAP
values remained relatively stable,
and no children discontinued
treatment due to adverse events.

Nusinersen yielded clinically
significant improvements in
motor function for patients with
later-onset SMA.

Finkel R. et
al. (2016)51

Phase II, open-label, multipledose dose-escalation study.
Participants (n = 20) were
patients with SMA type 1. 3 doses
of 6 or 12 mg nusinersen were
administered over three sessions.
Safety was assessed throughout
the trial. Event-free survival,
measures of motor function, and
pharmacokinetics of the drug in
autopsy tissue were evaluated.

Authors observed incremental
achievements of motor
milestones (p < 0.0001),
improvements in CHOP-INTEND
motor function scores (p =
0.0013), and increased
compound muscle action
potential amplitude of the ulnar
nerve (p = 0.0103) and peroneal
nerve (p < 0.0001), compared
with baseline. Autopsy showed
the distribution of the drug in
motor neurons in the spinal cord.
Adverse events were reported,
but authors considered them
unrelated to the study drug.

Nusinersen is safe for use in
patients with infantile-onset
SMA, has pharmacokinetics
consistent with its mechanism of
action, and shows promising
clinical efficacy.

De Vivo D.
et al.
(NURTURE,
2019)53

Phase II, open-label. Participants
(n = 25) were asymptomatic, but
all were documented to have
homozygous deletions of the
SMN1 gene with variable
numbers of SMN2 gene copies.
Four doses of 12 mg nusinersen
were administered, followed by
maintenance dosing every 119
days. Achievement of motor
milestones, event-free survival,
and need for ventilation was
analyzed ~2.9 years after the trial
began.

Four participants with
two SMN2 copies utilized
respiratory support for ≥ 6 h/day
for ≥ 7 consecutive days that was
initiated during acute, reversible
illnesses. All 25 participants
achieved the ability to sit without
support, 23/25 achieved walking
with assistance, and 22/25
achieved walking independently.
Eight infants had adverse events
considered possibly related to
nusinersen by the study
investigators.

Treatment of pre-symptomatic
SMA with nusinersen has an
acceptable safety level, and
evidence from the trial supports
its efficacy.

Finkel R. et
al.
(ENDEAR,
2017)54

Phase III, multicenter, doubleblind, placebo-controlled. 121
symptomatic infants (nusinersen
group, n = 80; placebo group, n =
41) were enrolled. Four doses of
12 mg nusinersen were
administered over 4 sessions.
Motor milestone achievements
and event-free survival were
compared between the drug

A significantly higher percentage
of infants in the nusinersen group
vs. the control group had a motor
response (51% vs. 0%), and the
likelihood of survival was also
higher (hazard ratio 0.53, p =
0.005). Participants with a
shorter duration of illness at the
onset of treatment were more
likely to derive benefit.

Nusinersen is effective in the
treatment of type 1 and type 2
SMA. Early detection may be
critical for optimal treatment
outcomes.
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group and placebo group.
AragonGawinska
K. et al.
(EAP,
2018)55

Phase III, extension trial for SMA
type 1 patients older than 7
months. 33 children between 8.3
and 113.1 months of age were
enrolled. Survival, respiratory,
and nutritional data were
collected.

Median progress on the modified
HINE-2 score was 1.5 points after
6 months of treatment (p <
0.001). The need for respiratory
support significantly increased
over time.

Nusinersen is also effective for
SMA type 1 in later stages of the
disease.

Mercuri E.
et al.
(CHERISH,
2018)56

Phase III, double-blind, placebocontrolled. Participants (n = 126;
n = 84 for the nusinersen group, n
= 42 for the control group) all had
symptom onset after 6 months of
age and received 4 doses of 12
mg nusinersen or 4 sham
procedures over 4 sessions.
Changes from the baseline of
HFMSE scores were evaluated.

The least-squares mean an
increase in HFMSE score from
baseline to month 15 was 4.0 in
the nusinersen group and -1.9 in
the control group. 57% of the
nusinersen group had an increase
in HFMSE score of ≥ 3 points, in
contrast to only 26% of the
control group (p < 0.001)

Nusinersen is effective in the
treatment of later-onset (types 2
and 3) SMA.

the specificity for its designated mRNA target, which modulates protein production. With the development of antisense technology came the FDA-approved nusinersen in
2016, which provided an optimistic approach to treating
SMA and other neurodegenerative diseases. Compared to
other pharmacologic treatment strategies mentioned,
nusinersen has been shown to increase exon 7 inclusions
to the SMN2 mRNA transcripts, enhancing SMN protein
production and, thus, increasing the amount of full-length
SMN proteins. It is available as an intrathecal injection requiring four initial loading doses followed by three maintenance injections annually supported by its long median

half-life. Studies investigating the timing of drug delivery in
mouse models of SMA report the best outcomes when drugs
are delivered early before any significant motor function is
lost.18,40 Phase III studies (CHERISH, ENDEAR, and NURTURE) have concluded to improve motor function in early
and late-onset individuals and reduce the chances of ventilator requirements in pre-symptomatic infants. Nusinersen
is a novel therapeutic approach that had consistent results
in all three studies and is proof of the concept for treating
SMA and other neurodegenerative disorders in the future.
Submitted: June 01, 2021 EST, Accepted: June 16, 2021 EST
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